ALAS1 and Acute hepatic porphyria: Givosiran is designed to inhibit hepatic 5-aminolevulinic acid synthase 1 (ALAS1) to treat acute hepatic porphyria caused by disruption of ALAS1 expression, which can result in accumulation of toxic metabolites.